Skip to main content
. 2019 Dec 12;12(1):1690959. doi: 10.1080/19420862.2019.1690959

Figure 3.

Figure 3.

CDC activity of bivalent anti-HER2 IgGs and their respective monovalent bispecific DuetMabs. (a–c) CDC activity of trastuzumab IgG and trastuzumab/NMGC DuetMab against SK-BR-3 (a), BT474 (b), and Calu-3 (c) cells at 10%, 5%, and 10% serum concentrations. (d–f) CDC activity of pertuzumab IgG and pertuzumab/NMGC DuetMab against SK-BR-3 (d), BT474 (e), and Calu-3 (f) cells at the corresponding serum concentrations as for the trastuzumab antibody set. (g–i) CDC activity of B1D2 IgG and B1D2/NMGC DuetMab against SK-BR-3 (g), BT474 (h), and Calu-3 (i) cells at the corresponding serum concentrations as for the trastuzumab antibody set. NMGC was used as an isotype control. Each point represents the mean values of triplicate wells, and the standard error of the mean is represented by error bars. See Table 3 for statistical analysis and P values.